1 |
Abacarvir/lamivudine () Clinical Pharmacology, Available at http://www.clinicalpharmacology-ip.com. ezproxylocal.library.nova.edu/Form/. Assessed on Jul 28, 2012.
|
2 |
Atazanavir() Clinical Pharmacology, Available at http://www.clinicalpharmacology-ip.com.ezproxylocal. library.nova.edu/Form/. Assessed on Jul 28, 2012.
|
3 |
Yeo JY, Shin HS, Chin BS, et al. Factors Associated with Renal Dysfunction, Including Highly Active Antiretroviral Therapy in Korean HIV-Infected Patient. Korean Journal of Clinical Pharmacy. 2012; 22(2): 95-102.
|
4 |
Carr A et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998 12: F51-F58.
DOI
ScienceOn
|
5 |
Currier JS. How to manage metabolic complications of HIV therapy: what to do while we wait for answers. AIDS Read 2000; 10: 162-169.
|
6 |
Lee D, Mathews WC.Prevalence and risk factors for hyperglycemia, dyslipidemia, and coronary disease among HIV-infected patients on initial protease inhibitor therapy [abstract 644]. In: 6th Conference on Retroviruses and Opportunistic Infections: program and abstracts (Chicago, 31 January to 4 February 1999). Available at http:// www.retroconference.org/99/default.htm.
|
7 |
Murillas J, Martin T, Ramos A, Portero JL. Atorvastatin for protease inhibitor-related hyperlipidaemia. AIDS 1999; 13: 1424-1425.
DOI
ScienceOn
|
8 |
Sullivan AK, Nelson MR. Marked hyperlipidaemia on ritonavir therapy. AIDS 1997; 11: 938-939.
|
9 |
Sullivan AK, Feher MD, Nelson MR, Gazzard BG. Marked hypertriglyceridaemia associated with ritonavir therapy. AIDS 1998; 12: 1393-1394.
DOI
ScienceOn
|
10 |
Smith KY. Selected Metabolic and Morphologic Complications Associated with Highly Active Antiretroviral Therapy. The Journal of Infectious Diseases 2002; 185 (Supp2): S123-S127.
DOI
|
11 |
Wohl DA, McComsey G, Tebas P et al. Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapy. Clin Infect Dis 2006; 43: 645-653.
DOI
ScienceOn
|
12 |
Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005; 352: 48-62.
DOI
ScienceOn
|
13 |
Lundgren JD, Battegay M, Behrens G, et al. European AIDS Clinical Society(EACS) guidelines on the prevention and management of metabolic disease in HIV. HIV Medcine 2008; 9: 72-81.
DOI
ScienceOn
|
14 |
Tenofovir, Emtricitabine () Clinical Pharmacology, Available at http://www.clinicalpharmacology-ip.com. ezproxylocal.library.nova.edu/Form/. Assessed on Jul 28, 2012.
|
15 |
HIV InSite. ARV Charts and Tables. Available at: http:// hivinsite.ucsf.edu/insite Assessed on Jul 27, 2012.
|
16 |
Nevirapine () Clinical Pharmacology, Available at http://www.clinicalpharmacology-ip.com.ezproxylocal.library.nova.edu/Form/. Assessed on Jul 28, 2012.
|
17 |
Nelfinavir, () Clinical Pharmacology, Available at http://www.clinicalpharmacology-ip.com.ezproxylocal. library.nova.edu/Form/. Assessed on Jul 28, 2012.
|
18 |
Lopinavir / ritonavir () Clinical Pharmacology, Available at http://www.clinicalpharmacology-ip.com. ezproxylocal.library.nova.edu/Form/. Assessed on Jul 28, 2012.
|
19 |
Law MG, Friis-Moller N, El-Sadr WM et al. The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D study. HIV Med 2006; 7: 218-230.
DOI
ScienceOn
|
20 |
Singh S, Willig JH, Mugavero MJ et al. Comparative Effectiveness and Toxicity of Statins Among HIV-Infected Patients. Clinical Infectious Diseases 2011; 52(3): 387-395.
DOI
ScienceOn
|
21 |
Guidelines for the Use of Antiretroviral Agents in HIV-1- Infected Adults and Adolescents, Available at http://www. aidsinfo.nih.gov/ContentFiles/Adultan-dAdolescentGL.pdf/. Assessed on Jun 20, 2012.
|
22 |
Julian Falutz. Therapy Insight: body-shape changes and metabolic complications associated with HIV and highly active antiretroviral therapy. NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM 2007; 3(9): 651-662.
DOI
ScienceOn
|
23 |
Bozzette SA., Ake CF, Tam HK, et al. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. The New England Journal of Medicine 2003; 348(8): 702-710.
DOI
ScienceOn
|
24 |
Palella FJ, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. The New England Journal of Medicine 1998; 338(13): 853-860.
DOI
ScienceOn
|
25 |
Van Wijk JP and Cabezas MC. Hypertriglyceridemia, Metabolic Syndrome, and Cardiovascular Disease in HIVInfected Patients: Effects of Antiretroviral Therapy and Adipose Tissue Distribution. International Journal of Vascular Medicine 2011; 2012: 1-13. doi:10.1155/2012/ 201027.
|